San Jose, California (PRWEB) October 29, 2013
Follow us on LinkedIn – ADME-toxicology testing is gaining significance in drug development. New drug discovery is a high risk, high cost proposition for pharmaceutical and biotech companies particularly due to the high attrition rate at every stage of drug development. The traditional drug development model inculcated toxicity and efficacy testing in in-vivo models, while ADME was used during compound selection. With time, however, the industry began to gain better understanding of the importance of structure-activity relationship in the design of new drugs, which led to improved focus on toxicology testing. A key reason attributed to late stage drug failures is the inability of drug candidates to mimic safety profiles witnessed in animal models in humans. Pharmaceutical companies are therefore focusing on incorporating toxicology testing in early drug development stages.
Due to synthesis of a large number of new molecules over the past few years, there has been an increase in the number of potential lead compounds, which is resulting in an increase in ADME-Tox screening. Advancements in ADME-Tox technology in terms of enhanced accuracy and predictability is expected to provide significant impetus to the market, as the industry moves towards ADME-Tox screening at early stages of drug development in order to reduce drug attrition rate at later stages. The introduction of ADME-Tox assays in the early stages of drug discovery process as a primary screening technology is also necessitating the adoption of flexible automation solutions. In addition, pharmaceutical companies are increasingly integrating ADME-Tox screening during the entire drug discovery and development process.
As stated by the new market research report on ADME-Toxicology Testing, the United States represents the largest market worldwide. Asia-Pacific is forecast to emerge as the fastest growing market with a CAGR of 22.9% over the analysis period. Growth in the region is led by government support and increasing number of collaborations between foreign pharmaceutical companies and research laboratories.
Toxicology Testing represent the largest product segment in the global ADME-Toxicology Testing market. Within Toxicology Testing, In Vivo Toxicology Testing represents the largest sub-segment. While in vivo technologies still account for a major share of demand, in vitro technologies are expected to spearhead global growth in the market in the coming years. This trend can be primarily attributed to increasing ethical concerns over the use of animals, and the resultant decrease in usage of animals in clinical trials. The market comprises Liver Hepatocytes, human PK predictive assays, CYP450 inhibition assays and Cell-Based Assays including BBB (Blood Brain Barrier), Caco-2 and MDR-1 BCRP.
Major players covered in the report include Accelrys Inc., ADMEcell Inc., BD Biosciences, Beckman Coulter Inc., BioreclamationIVT LLC, Cellartis AB, Cerep SA, Cyprotex PLC, Galapagos NV, Life Technologies Corporation, PerkinElmer Inc., and Simulations Plus Inc., among others.
The research report titled “ADME-Toxicology Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, drivers, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections for all major geographic markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK and Rest of Europe), Asia-Pacific and Rest of World. Product markets analyzed in the report include Toxicology (In-Vivo and In-Vitro) and ADME Testing.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/